State Street
XLO icon

State Street’s Xilio Therapeutics XLO Stock Holding History

State Street’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Hold
13,311
– – ﹤0.01% 4009
2026
Q1 		$112K Sell
13,311
-3
-0% -$25 ﹤0.01% 4006
2025
Q4 		$119K Buy
13,314
+1,608
+14% +$16.9K ﹤0.01% 4010
2025
Q3 		$138K Buy
11,706
+8,607
+278% +$86.2K ﹤0.01% 3991
2025
Q2 		$29.5K Hold
3,099
– – ﹤0.01% 4165
2025
Q1 		$31.4K Hold
3,099
– – ﹤0.01% 4151
2024
Q4 		$41.4K Hold
3,099
– – ﹤0.01% 4136
2024
Q3 		$34.2K Hold
3,099
– – ﹤0.01% 4159
2024
Q2 		$41.1K Buy
3,099
+1,978
+176% +$31K ﹤0.01% 4174
2024
Q1 		$16.9K Hold
1,121
– – ﹤0.01% 4298
2023
Q4 		$8.63K Hold
1,121
– – ﹤0.01% 4406
2023
Q3 		$33.1K Hold
1,121
– – ﹤0.01% 4366
2023
Q2 		$41.1K Hold
1,121
– – ﹤0.01% 4469
2023
Q1 		$49.9K Hold
1,121
– – ﹤0.01% 4504
2022
Q4 		$42.2K Hold
1,121
– – ﹤0.01% 4595
2022
Q3 		$46K Hold
1,121
– – ﹤0.01% 4676
2022
Q2 		$46K Sell
1,121
-5,583
-83% -$295K ﹤0.01% 4738
2022
Q1 		$664K Buy
6,704
+2,475
+59% +$392K ﹤0.01% 3937
2021
Q4 		$947K Buy
+4,229
New +$1.01M ﹤0.01% 3826

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street's XLO Position: Q2 2026 in Review

State Street held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 13,311 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #4009.

State Street first reported a position in XLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $947K in Q4 2021. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • State Street held 13,311 shares of Xilio Therapeutics worth $128K as of Q2 2026.
  • State Street left its Xilio Therapeutics share count unchanged in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4009 holding.
  • State Street first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • State Street's Xilio Therapeutics position peaked at $947K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.